Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls-A Prospective Cohort Study.
COVID-19
SARS-CoV-2
characteristics
comparison
controls
outcome
risk prediction
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 06 2021
17 06 2021
Historique:
received:
12
05
2021
revised:
09
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Most studies investigating early risk predictors in coronavirus disease 19 (COVID-19) lacked comparison with controls. We aimed to assess and directly compare outcomes and risk predictors at time of emergency department (ED) presentation in COVID-19 and controls. Consecutive patients presenting to the ED with suspected COVID-19 were prospectively enrolled. COVID-19-patients were compared with (i) patients tested negative (overall controls) and (ii) patients tested negative, who had a respiratory infection (respiratory controls). Primary outcome was the composite of intensive care unit (ICU) admission and death at 30 days. Among 1081 consecutive cases, 191 (18%) were tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 890 (82%) were tested negative (overall controls), of which 323 (30%) had a respiratory infection (respiratory controls). Incidence of the composite outcome was significantly higher in COVID-19 (23%) as compared with the overall control group (10%, adjusted-HR 2.45 (95%CI, 1.61-3.74),
Identifiants
pubmed: 34204453
pii: jcm10122672
doi: 10.3390/jcm10122672
pmc: PMC8234319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Schweizerische Herzstiftung
ID : NA
Organisme : Roche Diagnostics
ID : NA
Organisme : Cardiovascular Research Foundation Basel
ID : NA
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Swiss Med Wkly. 2020 Mar 24;150:w20229
pubmed: 32208495
J Med Virol. 2021 Apr;93(4):2141-2148
pubmed: 33090527
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Sci Rep. 2021 Mar 11;11(1):5803
pubmed: 33707550
Emerg Infect Dis. 2020 Oct;26(10):2504-2506
pubmed: 32610036
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Infect Dis. 2021 Apr;105:209-215
pubmed: 33607305
Br Med Bull. 2021 Jun 10;138(1):5-15
pubmed: 34057458
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Clin Microbiol Infect. 2021 Feb;27(2):295-296
pubmed: 32822885
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Dtsch Arztebl Int. 2020 May 8;117(19):329-335
pubmed: 32527378
Sci Rep. 2021 Mar 30;11(1):7193
pubmed: 33785830
Br J Anaesth. 2015 Feb;114(2):297-306
pubmed: 25431308
Fam Pract Manag. 2006 Apr;13(4):41-4
pubmed: 16671349
Mol Med Rep. 2020 Jul;22(1):9-19
pubmed: 32377709
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Int J Infect Dis. 2021 Feb;103:316-322
pubmed: 33279652
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
J Med Virol. 2021 Jan;93(1):257-261
pubmed: 32603481
Chest. 2020 Jul;158(1):97-105
pubmed: 32304772
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131